HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) All Versions of this Article: dc06-2127v1 30/5/1049    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kalantar-Zadeh, K. Articles by Sharma, K. Search for Related Content PubMed PubMed Citation Articles by Kalantar-Zadeh, K. Articles by Sharma, K. Social Bookmarking                What's this?

Hemoglobin A1c and Survival in Maintenance Hemodialysis Patients

¹Harold Simmons Center for Kidney Disease Research and Epidemiology
²Division of Nephrology and Hypertension, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, and David Geffen School of Medicine at UCLA, Torrance, CA 90502
³UCLA School of Public Health, Department of Epidemiology, Los Angeles, CA
⁴DaVita, Inc, El Segundo, CA 90245
⁵Division of Cardiology, Thomas Jefferson University, Philadelphia, PA 19107
⁶Center for Novel Therapies for Kidney Disease, Dorrance Hamilton Research Laboratories, Thomas Jefferson University, Philadelphia, PA 19107

kamkal{at}ucla.edu

ABSTRACT

Objective:: The optimal target for glycemic control has not been established in diabetic dialysis patients.

Research Design and Methods:: To address this question, the national database of a large dialysis organization (DaVita) was analyzed via time-dependent survival models with repeated measures.

Results:: Of 82,933 patients undergoing maintenance hemodialysis (MHD) in DaVita outpatient clinics over 3 yrs (7/01-6/04), 23,618 diabetic MHD patients had hemoglobin A1c (HbA1c) measurements at least once. Unadjusted survival analyses indicated paradoxically lower death hazard ratios (HR) with higher HbA1c values. However, after adjusting for potential confounders (demographics, dialysis vintage and dose, comorbidity, anemia and surrogates of malnutrition and inflammation), higher HbA1c values were incrementally associated with higher death risks. Compared to HbA1c in 5-6% range, the adjusted all-cause and cardiovascular death HR for HbA1c10% was 1.41 (95% confidence interval [CI]: 1.25-1.60) and 1.73 (95%CI: 1.44-2.08), respectively (p<0.001). The incremental increase in death risk for rising HbA1c values was monotonic and robust in non-anemic patients (Hb>11.0 g/dL). In subgroup analyses, the association between HbA1c>6% and increased death risk was more prominent among younger patients, those who had undergone dialysis >2 yrs, and those with higher protein intake (>1 gm/kg/day), blood hemoglobin (>11 g/dl) or serum ferritin values (>500 ng/ml).

Conclusions:: In diabetic MHD patients, the apparently counterintuitive association between poor glycemic control and greater survival is explained by such confounders as malnutrition and anemia. . All things equal, higher HbA1c is associated with increased death risk. Lower HbA1c levels not related to malnutrition or anemia appears associated with improved survival in MHD patients.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				L. Gnudi Serum intact parathyroid hormone in diabetic patients on haemodialysis: what is the treatment goal? Nephrol. Dial. Transplant., January 1, 2008; 23(1): 24 - 26. [Full Text] [PDF]